Co mówią badania kliniczne na temat peptydu miedziowego (GHK-Cu) i starzenia się skóry?

Clinical trials show that copper peptide improves many visible and structural signs of skin ageing, including density, thickness, firmness, elasticity, and overall skin appearance. These effects have been observed in controlled human studies using topical preparations for periods typically ranging from 8 to 12 weeks. Overall, the results indicate a consistent improvement in both skin appearance and function.

In placebo-controlled studies involving women with mild to advanced photoaging, the topical application of creams containing copper peptide led to measurable effects. A 12-week facial study with 71 women recorded an increase in skin thickness and density, a reduction in laxity, improved clarity, and a visible decrease in fine lines and wrinkles. Similar results were observed in other studies, including one with 67 women aged 50–59, where twice-daily application improved firmness, texture, and pigmentation, and also increased keratinocyte proliferation, indicating enhanced skin renewal processes at a cellular level.

These effects are linked to the role of the copper peptide in tissue remodelling and repair signalling. This peptide stimulates fibroblast activity, increases collagen and elastin synthesis, and enhances the production of growth factors such as VEGF and bFGF. It also supports angiogenesis and improves microcirculation, which facilitates nutrient delivery and tissue regeneration. At the same time, it reduces inflammation and oxidative stress associated with skin ageing.

Another significant mechanism is the impact on extracellular matrix turnover. Copper peptide regulates both collagen synthesis and degradation by interacting with matrix metalloproteinases (MMPs) and their inhibitors. This balanced remodelling improves the structural integrity of the skin, rather than merely increasing collagen quantity.

Despite these positive results, most studies focus on cosmetic applications, involve relatively small groups of participants, and have short observation periods. Long-term clinical data and standardised research protocols are still limited, and results may vary depending on the formulation, delivery system, and individual skin condition.

These results are based on controlled clinical and cosmetic studies and do not confirm broader medical or therapeutic effects.

Has copper peptide been studied for wrinkle reduction in humans?

Yes, copper peptide has been studied in clinical trials with humans and demonstrated measurable effects in reducing the depth and volume of wrinkles. Several controlled studies indicate a positive impact on both fine lines and deeper wrinkles with topical application of the peptide over a period of several weeks. These findings suggest a visible effect on skin appearance under specific research conditions.

In a randomised, double-blind clinical trial, participants used a copper peptide preparation twice daily for 8 weeks. Compared to the control serum, wrinkle volume decreased by approximately 55.8%, while their depth decreased by 32.8%. Compared to the commercial peptide product Matrixyl® 3000, the copper peptide showed a 31.6%greater reduction in wrinkle volume. This indicates a stronger effect within the specific study design.

Additional data comes from 12-week studies using face and eye creams. In one study involving 41 women, an eye cream containing copper peptide was more effective at reducing visible lines and wrinkles than a placebo and a vitamin K-based product. In addition to wrinkle reduction, improved skin density and thickness were also observed, which may contribute to a smoother appearance and less visible lines.

These effects are explained by several mechanisms of action. Copper peptide supports collagen and elastin production, improves the extracellular matrix structure, and increases fibroblast activity. It also promotes keratinocyte proliferation, which aids skin regeneration and leads to its smoothing. Additionally, its antioxidant and anti-inflammatory properties help to limit damage caused by UV radiation and oxidative stress, which accelerate wrinkle formation.

Despite these findings, it should be emphasised that most research concerns cosmetic applications and topical preparations. Effects can vary depending on the product's formulation, the degree to which the ingredient penetrates the skin, and the regularity of use. There is also a limited number of studies directly comparing copper peptide with medical therapies or evaluating long-term results.

These results are based on controlled human studies focused on skin appearance and should not be interpreted as equivalent to clinical treatment effects.

What effects concerning skin thickness and elasticity were observed in the studies?

Clinical trials demonstrate that copper peptides increase both skin thickness and elasticity, with improvements in these parameters consistently observed in multiple human studies using topical formulations over 8 to 12 weeks. These findings have been noted across various research projects, suggesting a reproducible effect under controlled conditions.

In controlled studies, creams containing copper peptides, applied to the skin of the face or body, led to a noticeable increase in the thickness of both the epidermis and dermis. For example, a 12-week study in women with photoaged skin noted a measurable increase in skin density and thickness and a reduction in laxity. Similar results were obtained in studies concerning the eye area and in trials where the product was applied to thigh skin. In these cases, histological analysis confirmed increased collagen production and improved structural organisation of the skin.

Improved elasticity was also observed repeatedly. Both in pilot studies and larger clinical trials, an increase in skin firmness and elasticity has been noted following regular use of copper peptide. These changes are most likely linked to increased elastin production and better alignment of collagen fibres. In one study, copper peptide also improved skin contrast and hydration, as well as smoothing its surface, reflecting an improvement in the skin's mechanical properties and overall quality.

The observed effects can be explained by changes occurring at a cellular level. Copper peptide activates fibroblasts, stimulating them to produce collagen, elastin and glycosaminoglycans. Together, these components contribute to increased skin thickness, elasticity and resilience. Additionally, copper peptide supports copper-dependent enzymes, such as lysyl oxidase, which are essential for cross-linking collagen and elastin fibres. This process strengthens the skin's structure and improves the functioning of these fibres.

Furthermore, it has been demonstrated that copper peptide enhances the expression of integrins and stem cell-related markers in epidermal cells. This suggests an improvement in the skin's regenerative capabilities, which may contribute to increased skin layer thickness and greater resistance to mechanical stress.

However, certain limitations must be taken into account. Differences in measurement methods, variations in product formulations, and the relatively short duration of studies can influence the results. Furthermore, most of the available data comes from cosmetic studies rather than long-term dermatological research.

Copper peptide used in research conditions is available via suppliers such as SemaxPolska. These results are based on controlled experimental and cosmetic studies and do not constitute confirmation of medical or therapeutic effects.